April 13th 2021, 3:00pm
A 500 mg dose of Tepmetko, a MET inhibitor, in patients with hepatocellular carcinoma who were previously treated with Nexavar led to a 12-week progression-free survival rate of 63.3%.
April 9th 2021, 6:00pm
CURE spoke with Dr. Marty T. Sellers and Dr. Laura M. Kulik, on behalf of the Blue Faery, about liver cancer and disease – its treatments, causes and areas outside of therapy.
March 19th 2021, 9:00pm
Patients with this liver cancer subtype do not need to be hospitalized to receive this treatment and, according to the agent’s manufacturer, Boston Scientific, can typically receive the therapy in approximately an hour during an outpatient procedure.
March 17th 2021, 6:00pm
Genomic testing has allowed patients to receive more specific drugs that target mutations in their tumors.
February 25th 2021, 10:00pm
Following resection with radiotherapy increased survival rates for patients compared with those who did not receive the additional treatment.
January 27th 2021, 7:00pm
There are multiple treatment patients for patients with cholangiocarcinoma, here's what you need to know about them.
In a phase 2 study of 24 patients with biliary cancer, Aliqopa in combination with Gemzar and chemotherapy led to a six-month progression-free survival rate of 51% with a median overall survival of 13.7 months.
January 21st 2021, 7:00pm
“Along with a tolerable safety profile and supportive quality of life, these final efficacy results demonstrate the clinical benefit of (Tibsovo) in (previously treated patients with IDH1-mutant cholangiocarcinoma), for which there is an urgent need for new therapies,” said an expert from Massachusetts General Hospital, who presented the data.
January 19th 2021, 7:00pm
“This is the longest survival seen in a phase 3 study of advanced liver cancer,” lead study author Dr. Richard S. Finn, of the UCLA Jonsson Comprehensive Cancer Center, said in a virtual presentation of the data.
January 14th 2021, 10:30pm
Patients with hepatocellular carcinoma who live in low-income and rural households are less likely to receive high quality care and therefore are more likely to be diagnosed with an advanced stage cancer.
Ayvakit Shows Promise for Patients with Gastrointestinal Stomach Tumors With Specific Mutation
Survivorship Champions
FDA Approves Opdivo for the Frontline Treatment of Gastric Cancer
Learning to be a Kinder Person After Cancer
